DiaMonTech GmbH, a young medical technology company, has received the CE certification for its first medical product "DMT Base". The device enables non-invasive blood glucose measurement using laser-based technology. The certification confirms that the patented technology meets the high safety and performance standards for medical devices required for market approval. The label is valid for all countries of the European Union.
"The CE label of our non-invasive blood glucose monitoring device is an important milestone for our company. It is backed by more than 20 years of intensive research and development work. Now our goal is to make this technology available to as many diabetes patients and as quickly as possible, thereby making their lives easier," says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.
The "DMT Base" can be used intuitively: the patient places his finger on a sensor field for a few seconds and the blood sugar level is shown on a display. The blood sugar level can thus be measured precisely and painlessly without a drop of blood. The measurement can be carried out as often as desired without consumables (test strips). For the user, the need to prick several times a day is eliminated.
The "DMT Base" is currently optimised for use in professional environments (e.g. diabetes centres). The smaller "DMT Pocket" is currently under development. This device is intended to be about the size of a smartphone and could therefore be a constant companion for diabetes patients.
About DiaMonTech
Founded in Berlin, Germany, in 2015, DiaMonTech is a medical technology company committed to improving health outcomes for people with diabetes and empowering them to take control of their lifelong health. Its pioneered and patented non-invasive “no prick” photothermal detection technology is fast and painless and doesn’t require needles or test strips. An industry first, DiaMonTech monitors the actual glucose molecules in skin, providing users with a more comprehensive and accurate reading comparable to invasive commercial devices. DiaMonTech achieved 99.1% accuracy in a test study with 100 people studied, received the CE mark as a medical device in April 2019 and is currently under FDA review. To support its mission, DiaMonTech is led by a world-class team of scientists, researchers and healthcare experts.
More information about DiaMonTech can be found at www.diamontech.de.
Press contact
Markus Teuber
E-mail: hello@diamontech.de
